Disease Info Card

Familial Hypobetalipoproteinemia

Information about Familial Hypobetalipoproteinemia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Familial Hypobetalipoproteinemia

Most recent studies have shown that Familial Hypobetalipoproteinemia shares some biological mechanisms with abetalipoproteinemia, acanthocytosis, atherosclerosis, chylomicron-retention-disease, coronary-heart-disease, diarrhea, fatty-liver, heart-diseases, hereditary-diseases, hypercholesterolemia, hypobetalipoproteinemias, hypocholesterolemia, hypolipoproteinemias, liver-diseases, malabsorption-syndrome, nonalcoholic-fatty-liver-disease, obesity, steatohepatitis, steatorrhea, steatosis.

Among the many pathways, these few ones have gauged particular interests from scientists studying Familial Hypobetalipoproteinemia, and have been seen in publications frequently: Aging, Cholesterol Esterification, Cholesterol Homeostasis, Cholesterol Transport, Chylomicron Assembly, Endocytosis, Excretion, Intestinal Absorption, Lipid Homeostasis, Mrna Splicing, Mrna Transcription, Pathogenesis, Pinocytosis, Regulation Of Cholesterol Homeostasis, Reverse Cholesterol Transport, Secretion, Secretory Pathway, Translation, Transport, Triglyceride Transport

Quite a number of genes have been found to play important roles in Familial Hypobetalipoproteinemia, such as APOA1, APOB, APOC3, APOE, CD55, DBT, INS, LDLR, LPA, LPL, MT1B, MTTP, NPC1L1, PCSK9, SAR1B, SEPSECS, TG. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.